-
Birth weight discordancy of > 15% for same sex and > 30% for different sex confer greatest risk of adverse perinatal outcomes in the absence of abruption.
-
The data in this case-control study of combined estrogen plus progestin therapy revealed an increased risk of breast cancer, particularly invasive lobular tumor, regardless of whether the progestin component was taken sequentially or continuously.
-
In an intent-to-treat analysis, the use of conjugated equine estrogen combined with continuous medroxyprogesterone acetate by menopausal women increased the hazard ratio of invasive breast cancer to 1.24.
-
-
-
The Women's Health Initiatives was halted a year ago, but fallout
from this landmark study continues. The study was designed to identify
the risks or benefits of estrogen plus progesterone vs placebo in
healthy postmenopausal women.
-
This review will provide an overview of SARS for the primary care physician, including epidemiology, etiology, review of the clinical and laboratory features as well as diagnosis, therapy, and prevention of SARS.
-
Influenza Vaccination and Reduction in Hospitalizations; Screening Men
for Prostate and Colorectal Cancer; Weight Loss in CHF and Treatment
with ACE-I; Impaired Fasting Glucose vs Impaired Glucose Tolerance;
Risk Stratification in Long-QT Syndrome; EBCT, Motivation, Behavioral
Change, and Cardiovascular Risk Profile
-
-
What is your clinics protocol when it comes to emergency contraception (EC)? New research indicates that because the Yuzpe EC regimen of combined oral contraceptives (OCs) is at least partially effective when started up to 120 hours after unprotected intercourse, current protocols may be too restrictive.1